9 stories mentioning DFTXUpdated 3d ago
Every FINWIRES story that references DFTX, newest first.
Definium Therapeutics, Inc. (DFTX) has an average rating of buy and mean price target of $60, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Nexentis Technologies (NXTS) said Monday its subsidiary, MitoCareX Bio, has entered into an engagement with Boltz, an AI research lab, to accelerate the identification of novel small-molecule scaffolds targeting selected solute carrier proteins of interest to MitoCareX's pipeline.Shares jumped over 200% as trading volume catapulted to over 55 million from a daily average of about 208,000.AbbVie (ABBV) agreed to acquire Apogee Therapeutics (APGE) for $135.11 per share in cash for a total equity value of $10.9 billion, the companies said Monday.Shares of Apogee soared 47%, with intraday trading volume of over 47.1 million against a daily average of about 975,000.Definium Therapeutics (DFTX) reported positive topline results from a phase 3 Emerge study of DT120 orally disintegrating tablet in major depressive disorder.RBC Capital raised its price target to $57 from $36, while maintaining its outperform rating.Shares surged 52% amid a jump in intraday trading volume to over 16 million from a daily average of roughly 1.9 million.Price: $15.55, Change: $+10.47, Percent Change: +206.08%
Healthcare stocks were higher Monday afternoon, with the NYSE Healthcare Index rising 1.4% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.2%.The iShares Biotechnology ETF (IBB) rose 1.9%.In corporate news, AbbVie (ABBV) has agreed to acquire Apogee Therapeutics (APGE) in an all-cash deal worth about $10.9 billion, as the drugmaker looks to boost its immunology portfolio and accelerate its clinical presence in the respiratory segment. AbbVie shares jumped past 7%, and Apogee surged 46%.Jaguar Health (JAGX) shares climbed up past 9% after the firm said Monday its board has started a process to explore strategic alternatives to maximize shareholder value.Definium Therapeutics (DFTX) shares soared 55% after the firm said the phase 3 Emerge trial of a single 100-microgram dose of DT120 orally disintegrating tablet in major depressive disorder met the primary endpoint, and all key secondary endpoints.
Definium Therapeutics, Inc. (DFTX) has an average rating of buy and mean price target of $42, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $38.10, Change: $+13.62, Percent Change: +55.64%
Healthcare stocks were flat to lower premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1% and the iShares Biotechnology ETF (IBB) inactive.AbbVie (ABBV) has agreed to acquire Apogee Therapeutics (APGE) for $135.11 per share in cash for a total equity value of $10.9 billion. Shares of Apogee Therapeutics were up nearly 47% pre-bell, while AbbVie rose 2.3%.Definium Therapeutics (DFTX) shares were up more than 60% after the company said the phase 3 Emerge trial of a single 100-microgram dose of DT120 orally disintegrating tablet in major depressive disorder met the primary endpoint, along with all key secondary efficacy endpoints.MapLight Therapeutics' (MPLT) phase 2 trial of ML-004 in autism spectrum disorder failed to meet its primary endpoint in social communication, the company said. MapLight Therapeutics stock was up 1.6% premarket.
Definium Therapeutics' (DFTX) Phase 3 Emerge trial of a single 100-microgram dose of DT120 orally disintegrating tablet in major depressive disorder met the primary endpoint along with all key secondary efficacy endpoints, the company said Monday.The study showed an 8.1-point placebo-adjusted decline in Montgomery-Asberg Depression Rating Scale scores at Week 6 (pThe company also reported a 14.2-point placebo-adjusted improvement at Week 1 (pDT120 ODT was generally well tolerated, with mostly mild to moderate adverse events, no serious adverse events and no new safety signals, including no increase in suicidal ideation or behavior, Definium said.Definium Therapeutics shares were up 32% in premarket trading.
Shares of some psychedelic drug companies gained Friday morning after the US Food and Drug Administration said it was launching regulatory actions to back the development of psychedelic therapies to treat mental illness.Cybin (HELP) shares jumped past 4%, Psyence Biomedical (PBM) shares climbed 7%, and Clearmind Medicine (CMND) shares were up 2.4%.The FDA's move builds on President Donald Trump's recent executive order directing the Department of Health and Human Services to accelerate access to treatments for people with serious mental illness, the FDA said.The drugs have the potential to address mental health diseases like treatment-resistant depression, alcoholism and substance abuse, said FDA Commissioner Marty Makary.The agency said it is issuing national priority vouchers to three companies researching psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, and methylone for post-traumatic stress disorder.The agency said it is also allowing an early-phase trial of noribogaine hydrochloride to proceed following an investigational new drug filing. The sponsor is investigating noribogaine to potentially treat alcohol use disorder, the FDA said, adding the move will allow the company developing the new drug, DemeRx NB, to start a phase 1 trial in the US.The agency said it will release final guidance "imminently" to provide recommendations to sponsors developing psychedelic medications.Price: $8.89, Change: $-0.27, Percent Change: -2.90%
Definium Therapeutics, Inc. (DFTX) has an average rating of Buy and mean price target of $38.87, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $22.79, Change: $-0.29, Percent Change: -1.26%
Definium Therapeutics, Inc. (DFTX) has an average rating of buy and mean price target of $36.67, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
